GlassScriptPhysician profile
Miguel Ortega
NPI 1023775939
$3,270.38
in general payments reported to CMS, 2019-2025
17 companies · $735 in 2025
The $735 reported for 2025 was more than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,225 · 2023: $248 · 2024: $1,062 · 2025: $735.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,939 · Education: $106.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,939.46 |
| Education | $105.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $729.00 | 2022-2025 | Aristada, Lybalvi, Aristada Initio |
| Abbvie INC. | $540.17 | 2022-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $442.63 | 2022-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $374.79 | 2022-2025 | Abilify Maintena, Abilify Asimtufii, Rexulti |
| Teva Pharmaceuticals USA, INC. | $261.31 | 2022-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Vanda Pharmaceuticals INC. | $178.86 | 2022-2025 | Fanapt, Hetlioz |
| Sunovion Pharmaceuticals INC. | $157.03 | 2022 | |
| Axsome Therapeutics, INC. | $146.03 | 2024-2025 | Auvelity |
| Neurocrine Biosciences, INC. | $107.44 | 2022-2025 | Ingrezza |
| Janssen Pharmaceuticals, INC | $87.22 | 2024-2025 | Invega Sustenna |
| E.R. Squibb & Sons, L.L.C. | $81.71 | 2024-2025 | Cobenfy |
| Lundbeck LLC | $58.38 | 2022-2024 | Abilify Asimtufii |
| Sage Therapeutics, LLC | $25.94 | 2025 | Zurzuvae |
| Indivior INC. | $24.89 | 2024 | Perseris |
| Almatica Pharma LLC | $24.35 | 2024 | Loreev Xr |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $15.69 | 2024 | Quviviq |
| Takeda Pharmaceuticals U.S.A., INC. | $14.94 | 2024 | Trintellix |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Miguel Ortega listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.